• 1
    Miller R, Frame B, Corrigan BW, et al. Mixed effects modeling of pregabalin response in patients with refractory partial seizures [Abstract]. Clin Pharmacol Ther 2001;69: 78.
  • 2
    Ramsay RE, Kugler AR, Anhut H, et al. Pregabalin adjunctive therapy in patients with partial seizures [Abstract]. Epilepsia 2001;42(suppl 7):211.
  • 3
    Robbins JL, Kugler AR, Anhut H, et al. Pregabalin shows anticonvulsant activity onset by second day [Abstract]. Epilepsia 2001;42(suppl 7):2112.
  • 4
    Minecan DN, Passaro EA, Murugaiyan P, et al. Long-term efficacy and safety of pregabalin for the treatment of partial onset seizures [Abstract]. Epilepsia 2001;42(suppl 7):184.
  • 5
    Arroyo S, Anhut H, Kugler AR, et al. Pregabalin: add-on treatment: a double-blind, placebo-controlled multicenter study in patients with partial seizures. Epilepsia 2004;45: 207.
  • 6
    Beydoun A, Uthman BM, Kugler AR, et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005;64: 47580.
  • 7
    French JA, Kugler AR, Robbins JL, et al. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003;60: 16317.
  • 8
    Uthman BM, Lee CM, Spiegel K. Long-term seizure freedom in patients with partial seizures treated with add-on pregabalin: an analysis of four, long-term, open-label trials. Epilepsia 2004;45(suppl 7):1393.
  • 9
    Lauria-Horner BA, Pohl RB. Pregabalin: a new anxiolytic. Expert Opin Invest Drugs 2003;12: 66372.
  • 10
    Dooley DJ, Donovan CM, Meder WP, et al. Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked. Synapse 2002;45(suppl 1):17190.
  • 11
    Gee NS, Brown JP, Dissanayake VU, et al. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2δ subunit of a calcium channel. J Biol Chem 1996;271: 576876.
  • 12
    Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002;42: 22936.
  • 13
    Dooley DJ, Mieske CA, Borosky SA. Inhibition of K+-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000;280: 10710.
  • 14
    Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent nodulation of [3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000;295: 108693.
  • 15
    Maneuf YP, Hughes J, McKnight AT. Gabapentin inhibits the substance P–facilitated K+-evoked release of [3H]glutamate from rat caudal trigeminal nucleus slices. Pain. 2001;93: 1916.
  • 16
    Taylor CP. The biology and pharmacology of calcium channel a2-d proteins. CNS Drug Rev 2004;10: 15964.
  • 17
    Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res 1999;34: 141.
  • 18
    Welty D, Wang Y, Busch JA, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of CI-1008 (pregabalin) and gabapentin in rats with maximal electroshock [Abstract]. Epilepsia 1997;38(suppl 8):35. abstract 1.110.
  • 19
    Corrigan BW, Pool WF, Posvar EL, et al. Metabolic disposition of pregabalin in healthy volunteers [Abstract]. Clin Pharmacol Ther 2001;69: 18.
  • 20
    Bockbrader HN, Burger PJ, Corrigan BW, et al. Population pharmacokinetic (PK) analysis of pregabalin (PGB) in adult patients with refractory partial seizures [Abstract]. Epilepsia 2001;42(suppl 7):84.
  • 21
    Randinitis EJ, Posvar EL, Alvey CW, et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 2003;43: 27783.
  • 22
    Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995;15: 38798.
  • 23
    Besag FMC, McShane T, Neville B, et al. Factors associated with serious skin reactions in children aged 12 years and undertaking lamotrigine. Dev Med Child Neurol 1999;41: 679.
  • 24
    Guberman AH, Besag FMC, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999;40: 98591.
  • 25
    Messenheimer J, Mullens EL, Giorgi L, et al. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998;18: 28196.
  • 26
    Data on file. Parke-Davis Pharmaceutical Research Protocol 2000;10083.
  • 27
    Data on file. Parke-Davis Pharmaceutical Research Protocol 2000;1008128-0.
  • 28
    Windsor BL, Radulovic LL. Measurement of a new anticonvulsant, (S)-3-(aminomethy1)-5-methylhexanoic acid, in plasma and milk by high-performance liquid chromatography. J Chromat (Biomed Appl) 1995;674: 143.
  • 29
    Busch JA, Strand JA, Posvar EL, et al. Pregabalin (CI-1008) multiple-dose pharmacokinetics and safety/tolerance in healthy volunteers. Pharm Sci 1999;1(suppl 4):2033.
  • 30
    Data on file. Parke-Davis Pharmaceutical Research Protocol 2000;10082.
  • 31
    Bockbrader HN, Burger PJ, Kugler AR, et al. Population pharmacokinetic (PK) analyses of commonly prescribed antiepileptic drug (AEDs) coadministered with pregabalin (PGB) in adult patients with refractory partial seizures [Abstract]. Epilepsia 2001;42(suppl 7):84.
  • 32
    Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001;42: 125560.
  • 33
    Reilly JG, Ayis SA, Ferrier IN, et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000;355: 104852.